$8.56
0.12%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US9842411095
Symbol
YMAB

Y-mAbs Therapeutics, Inc. Stock price

$8.56
+4.37 104.30% 1M
+3.37 64.93% 6M
+0.73 9.32% YTD
-5.75 40.18% 1Y
-7.35 46.20% 3Y
-32.26 79.03% 5Y
-15.44 64.33% 10Y
-15.44 64.33% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.01 0.12%
ISIN
US9842411095
Symbol
YMAB
Industry

Key metrics

Basic
Market capitalization
$388.0m
Enterprise Value
$325.8m
Net debt
positive
Cash
$62.3m
Shares outstanding
45.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.5 | 4.6
EV/Sales
3.8 | 3.9
EV/FCF
negative
P/B
4.4
Financial Health
Equity Ratio
76.7%
Return on Equity
-32.2%
ROCE
-28.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$85.4m | $84.5m
EBITDA
$-26.3m | $-48.2m
EBIT
$-26.7m | $-46.9m
Net Income
$-22.2m | $-38.1m
Free Cash Flow
$-17.9m
Growth (TTM | estimate)
Revenue
-1.3% | -3.7%
EBITDA
2.6% | -65.4%
EBIT
3.6% | -58.2%
Net Income
9.7% | -28.2%
Free Cash Flow
-42.8%
Margin (TTM | estimate)
Gross
81.8%
EBITDA
-30.8% | -57.1%
EBIT
-31.2%
Net
-26.0% | -45.0%
Free Cash Flow
-21.0%
More
EPS
$-0.5
FCF per Share
$-0.4
Short interest
4.3%
Employees
104
Rev per Employee
$840.0k
Show more

Is Y-mAbs Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Y-mAbs Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:

14x Buy
82%
1x Hold
6%
2x Sell
12%

Analyst Opinions

17 Analysts have issued a Y-mAbs Therapeutics, Inc. forecast:

Buy
82%
Hold
6%
Sell
12%

Financial data from Y-mAbs Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
85 85
1% 1%
100%
- Direct Costs 16 16
59% 59%
18%
70 70
9% 9%
82%
- Selling and Administrative Expenses 50 50
0% 0%
58%
- Research and Development Expense 45 45
17% 17%
53%
-26 -26
3% 3%
-31%
- Depreciation and Amortization 0.35 0.35
45% 45%
0%
EBIT (Operating Income) EBIT -27 -27
4% 4%
-31%
Net Profit -22 -22
10% 10%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Y-mAbs Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Y-mAbs Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
NEW YORK CITY and NEW ORLEANS, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Y-mAbs Therapeutics, Inc. (NasdaqGS: YMAB) to SERB Pharmaceuticals. Under the terms of the proposed transaction, shareholders of Y-mAbs will receive $8.60 in cash for each share ...
Neutral
Business Wire
26 days ago
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Y-mAbs (NASDAQ: YMAB) for possible breaches of fiduciary duty and other violations of law in its transaction with SERB Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender...
Positive
The Motley Fool
26 days ago
Y-mAbs Therapeutics (YMAB), a biopharmaceutical company focused on developing and commercializing antibody-based cancer therapies, reported its second quarter 2025 results on August 8, 2025. The company beat expectations on both revenue and earnings per share, posting GAAP revenue of $19.5 million against a GAAP consensus of $18.4 million, and GAAP EPS of ($0.07) compared to an analyst estimate...
More Y-mAbs Therapeutics, Inc. News

Company Profile

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Head office United States
CEO Michael Rossi
Employees 104
Founded 2015
Website www.ymabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today